AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by analysts at Citigroup Inc. in a report issued on Friday.
Other equities research analysts have also recently issued research reports about the stock. Deutsche Bank AG reiterated a “buy” rating and set a GBX 5,600 ($73.10) price target on shares of AstraZeneca plc in a report on Tuesday, June 14th. Berenberg Bank reiterated a “buy” rating and set a GBX 4,950 ($64.61) price target on shares of AstraZeneca plc in a report on Thursday, June 9th. Societe Generale reiterated a “buy” rating and set a GBX 6,900 ($90.07) price target on shares of AstraZeneca plc in a report on Friday, June 24th. Bryan, Garnier & Co reiterated a “buy” rating on shares of AstraZeneca plc in a report on Thursday, July 28th. Finally, BNP Paribas set a GBX 5,300 ($69.18) price target on shares of AstraZeneca plc and gave the company a “buy” rating in a report on Tuesday, August 2nd. Five research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. AstraZeneca plc has an average rating of “Hold” and an average target price of GBX 4,926.80 ($64.31).
Shares of AstraZeneca plc (LON:AZN) opened at 5158.00 on Friday. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The firm’s 50-day moving average is GBX 5,025.19 and its 200-day moving average is GBX 4,361.62. The company’s market cap is GBX 65.25 billion.
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were issued a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.